Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Affiliations

• ¹ Division of Oncology, Washington University School of Medicine and Alvin J. Siteman Cancer Center, Saint Louis, MO, USA.
• ² Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
• ³ Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
• ⁴ Medical Oncology, Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, VA, USA.
• ⁵ Merck S.L.U, Mollet del Valles, Spain, an affiliate of Merck KGaA, Darmstadt, Germany.
• ⁶ The Healthcare Business of Merck KGaA, Darmstadt, Germany.
• ⁷ Oncology Global Clinical Development, Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
• ⁸ Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. jordan.berlin@vumc.org.